Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value

BACKGROUND: Despite the widespread use of neoadjuvant chemotherapy in breast cancer patients, prediction of individual response to treatment remains an unsolved clinical problem. Particularly, administration of an inefficient chemotherapeutic regimen should be avoided. Therefore, a better understand...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Michlmayr, A, Bachleitner-Hofmann, T, Baumann, S, Marchetti-Deschmann, M, Rech-Weichselbraun, I, Burghuber, C, Pluschnig, U, Bartsch, R, Graf, A, Greil, R, Allmaier, G, Steger, G, Gnant, M, Bergmann, M, Oehler, R
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2010
Konular:
Translational Therapeutics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2967072/
https://ncbi.nlm.nih.gov/pubmed/20877360
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605909
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller